| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 0.4300 +48.84% on 04/09/25 |
Period Open: 0.8637
| 0.9230 -30.66% on 03/24/25 | -0.2237 (-25.90%) since 03/21/25 |
| 3-Month | 0.4300 +48.84% on 04/09/25 |
Period Open: 0.9180
| 1.0800 -40.74% on 02/14/25 | -0.2780 (-30.28%) since 01/22/25 |
| 52-Week | 0.4300 +48.84% on 04/09/25 |
Period Open: 1.3600
| 1.9280 -66.80% on 05/13/24 | -0.7200 (-52.94%) since 04/22/24 |
For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...
The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...
Jonathan Zalevsky, the Chief R&D Officer of $NKTR ($NKTR), sold 7,785 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.1%...
This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.
/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...
/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...
Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab).The company announced that a phase III study, MUSETTE, which compared...
Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...
The S&P 500 wrapped up the worst quarter since the third quarter of 2022, plunging 4.6%, due to escalating trade tensions and concerns over stagflation.The Trump administration imposed tariffs on Canada,...
Johnson & Johnson JNJ announced that a bankruptcy court in Texas has rejected its bankruptcy plan to resolve talc lawsuits for the third time.J&J faces more than 62,000 lawsuits for its talc-based products,...
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.
As the US stock market prepares to open on Wednesday, March 19 investors are bracing themselves for another day of volatility. The Federal Reserve’s interest rate decision, scheduled for later today,...
Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.
1 Healthcare Stock to Target This Week and 2 to Turn Down
Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...
Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...
Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab).The company announced that a phase III study, MUSETTE, which compared...
Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...
The S&P 500 wrapped up the worst quarter since the third quarter of 2022, plunging 4.6%, due to escalating trade tensions and concerns over stagflation.The Trump administration imposed tariffs on Canada,...
Johnson & Johnson JNJ announced that a bankruptcy court in Texas has rejected its bankruptcy plan to resolve talc lawsuits for the third time.J&J faces more than 62,000 lawsuits for its talc-based products,...
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.
As the US stock market prepares to open on Wednesday, March 19 investors are bracing themselves for another day of volatility. The Federal Reserve’s interest rate decision, scheduled for later today,...
Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.
1 Healthcare Stock to Target This Week and 2 to Turn Down
Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...
Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| NKTR | -30.28% | |
| Nektar Therapeutics | ||
| QQQS | 0.49% | -27.81% |
| Invesco Nasdaq Future Gen 200 ETF | ||
| IWC | 0.03% | -20.80% |
| Micro-Cap Ishares ETF | ||
| GSSC | 0.02% | -17.57% |
| GS Activebeta U.S. Small Cap Equity ETF | ||
| PRFZ | 0.01% | -17.93% |
| FTSE RAFI US 1500 Small/Mid Invesco ETF | ||
| VTWV | 0.01% | -16.92% |
| Russell 2000 Value Vanguard | ||
| 3rd Resistance Point | 0.6854 |
| 2nd Resistance Point | 0.6677 |
| 1st Resistance Point | 0.6468 |
| Last Price | 0.6445 |
| 1st Support Level | 0.6082 |
| 2nd Support Level | 0.5905 |
| 3rd Support Level | 0.5696 |
| 52-Week High | 1.9280 |
| Fibonacci 61.8% | 1.3558 |
| Fibonacci 50% | 1.1790 |
| Fibonacci 38.2% | 1.0022 |
| Last Price | 0.6445 |
| 52-Week Low | 0.4300 |
